SRTA
Strata Critical Medical, Inc. NASDAQ Listed Nov 5, 2019$5.30
-1.12%
vs $5.36
Mkt Cap $437.0M
52w Low $3.77
56.7% of range
52w High $6.47
50d MA $5.48
200d MA $4.97
P/E (TTM)
8.6x
EV/EBITDA
—
P/B
1.6x
Debt/Equity
0.0x
ROE
14.8%
P/FCF
-7.5x
RSI (14)
36.20
ATR (14)
$0.28
Beta
2.11
50d MA
$5.48
200d MA
$4.97
Avg Volume
1.2M
Strata Critical Medical, Inc. provides time critical logistics solutions and specialized medical services to healthcare providers across the United States. The company operates as both an air and ground transporter of human organs for transplant. The company was formerly known as Blade Air Mobility, Inc. and change its name to Strata Critical Medical, Inc. in August 2025. The company was founded in 2014 and is headquartered in New York, New York.
31 Hudson Yards · New York, NY 10001 · US
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mar 3, 2026 | BMO | 0.01 | -0.06 | -721.0% | 4.80 | +1.0% | +1.9% | -2.9% | -4.4% | +0.7% | +1.8% | — |
| Nov 10, 2025 | BMO | -0.02 | -0.06 | -200.0% | 4.85 | -1.0% | +3.9% | +1.2% | -4.1% | -2.0% | -7.1% | — |
| Aug 5, 2025 | BMO | -0.04 | -0.05 | -25.0% | 4.16 | -1.2% | -7.0% | -2.6% | +4.5% | +7.4% | +6.4% | — |
| May 12, 2025 | BMO | -0.11 | -0.04 | +63.6% | 3.46 | -0.3% | -0.3% | +0.3% | -1.4% | +3.2% | -2.6% | — |
| Mar 13, 2025 | BMO | -0.12 | -0.12 | +0.0% | 3.03 | +2.6% | +3.6% | +1.3% | -3.8% | -1.3% | -0.3% | — |
| Nov 12, 2024 | BMO | -0.06 | -0.03 | +50.0% | 3.49 | +1.4% | +4.9% | -6.6% | -7.6% | -1.9% | +6.1% | — |
| Aug 7, 2024 | BMO | -0.06 | -0.06 | +0.0% | 2.77 | +6.1% | +17.3% | -7.4% | -4.7% | +4.9% | -3.7% | — |
| May 7, 2024 | BMO | -0.13 | -0.06 | +53.8% | 3.58 | -0.6% | -2.2% | +2.6% | -2.5% | -3.7% | +9.2% | — |
| Mar 12, 2024 | BMO | -0.13 | -0.23 | -76.9% | 2.78 | +2.9% | -2.5% | -3.3% | +3.1% | -5.6% | -3.9% | — |
| Nov 8, 2023 | BMO | -0.10 | 0.00 | +103.6% | 2.94 | +1.4% | +7.1% | +1.3% | +2.8% | +8.2% | +4.2% | — |
| Aug 9, 2023 | BMO | -0.14 | -0.11 | +21.4% | 3.82 | +1.0% | -3.5% | +2.6% | -1.3% | -4.8% | -1.1% | — |
| May 11, 2023 | BMO | -0.21 | -0.14 | +33.3% | 3.09 | +1.0% | +1.9% | -1.6% | -4.5% | +3.0% | +3.0% | — |
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sep 17 | Lake Street | Maintains | Buy → Buy | — | $4.90 | $5.00 | +2.0% | +6.1% | +12.1% | -2.1% | +2.8% | -5.3% |
| Oct 29 | JP Morgan | Maintains | Overweight → Overweight | — | $3.79 | $3.79 | +0.0% | +0.5% | -1.8% | -3.7% | +0.0% | -0.3% |
| Aug 22 | Citigroup | Maintains | Buy → Buy | — | $3.58 | $3.61 | +0.8% | +0.6% | -4.2% | -8.7% | -1.3% | +4.2% |
| Aug 10 | Credit Suisse | Maintains | Outperform → Outperform | — | $3.82 | $3.86 | +1.0% | -3.5% | +2.6% | -1.3% | -4.8% | -1.1% |
| May 12 | Oppenheimer | Maintains | Outperform → Outperform | — | $3.09 | $3.12 | +1.0% | +1.9% | -1.6% | -4.5% | +3.0% | +3.0% |
| May 12 | Credit Suisse | Maintains | Outperform → Outperform | — | $3.09 | $3.12 | +1.0% | +1.9% | -1.6% | -4.5% | +3.0% | +3.0% |
| Mar 15 | Credit Suisse | Maintains | Outperform → Outperform | — | $3.52 | $3.50 | -0.6% | +3.4% | -5.5% | -9.0% | -2.2% | +6.5% |
| Mar 15 | JP Morgan | Maintains | Overweight → Overweight | — | $3.52 | $3.50 | -0.6% | +3.4% | -5.5% | -9.0% | -2.2% | +6.5% |
| Mar 15 | Oppenheimer | Maintains | Outperform → Outperform | — | $3.52 | $3.50 | -0.6% | +3.4% | -5.5% | -9.0% | -2.2% | +6.5% |
| Jan 26 | JP Morgan | Maintains | Overweight → Overweight | — | $4.34 | $4.38 | +0.9% | +1.2% | +2.7% | -2.9% | +1.8% | +2.2% |
| Nov 10 | Credit Suisse | Maintains | Outperform → Outperform | — | $4.56 | $4.81 | +5.5% | +1.1% | -1.3% | +3.5% | +6.2% | -2.0% |
| Oct 18 | JP Morgan | Maintains | Overweight → Overweight | — | $3.84 | $3.92 | +2.2% | -5.7% | +1.9% | +3.3% | +2.6% | -0.8% |
| May 12 | Deutsche Bank | Maintains | Buy → Buy | — | $5.60 | $5.42 | -3.2% | +4.8% | +13.3% | -0.3% | +5.9% | +0.1% |
| May 11 | Credit Suisse | Maintains | Outperform → Outperform | — | $6.15 | $6.05 | -1.6% | -8.9% | +4.8% | +13.3% | -0.3% | +5.9% |
| Sep 28 | Oppenheimer | Maintains | Outperform → Outperform | — | $11.27 | $11.07 | -1.8% | -3.5% | -5.2% | +0.9% | +1.0% | -3.3% |
| Sep 9 | JP Morgan | Maintains | Overweight → Overweight | — | $8.79 | $9.50 | +8.1% | +18.8% | -5.7% | -5.7% | +3.9% | +3.7% |
| Sep 2 | Deutsche Bank | Maintains | Buy → Buy | — | $8.85 | $8.95 | +1.1% | +1.6% | -1.6% | +0.3% | -1.0% | +18.8% |
| Sep 1 | Deutsche Bank | Maintains | Buy → Buy | — | $8.51 | $8.65 | +1.6% | +4.0% | +1.6% | -1.6% | +0.3% | -1.0% |
| Jun 3 | Citigroup | Maintains | Buy → Buy | — | $9.77 | $10.10 | +3.4% | +12.4% | -2.2% | -1.2% | -2.9% | -0.7% |
| Date | Insider | Title | Type | Shares | Price | Value | Owned After | D1% | D5% |
|---|---|---|---|---|---|---|---|---|---|
| Jun 8, 2026 | Wunsch Scott MOff | CEO, Logistics | Sell | 5,550 | $5.87 | $33K | 625,574 | +0.18% | -0.86% |
| Jun 8, 2026 | Tomkiel Melissa M.Dir/Off | Co-CEO and General Counsel | Sell | 29,730 | $5.87 | $175K | 1,892,774 | +0.18% | -0.86% |
| Jun 8, 2026 | Cohen AmirOff | Chief Accounting Officer | Sell | 4,655 | $5.87 | $27K | 146,608 | +0.18% | -0.86% |
| Jun 8, 2026 | Heyburn William A.Dir/Off | Co-CEO and CFO | Sell | 31,671 | $5.87 | $186K | 1,548,997 | +0.18% | -0.86% |
| May 22, 2026 | Cohen AmirOff | Chief Accounting Officer | Sell | 40,575 | $5.91 | $240K | 151,263 | +1.95% | +2.29% |
| May 21, 2026 | Cohen AmirOff | Chief Accounting Officer | Sell | 10,300 | $5.79 | $60K | 191,838 | +1.95% | +2.29% |
| May 11, 2026 | Cohen AmirOff | Chief Accounting Officer | Sell | 14,306 | $5.79 | $83K | 202,138 | +0.74% | +6.13% |
8-K
Strata Critical Medical, Inc. -- 8-K Filing
I cannot provide a meaningful analysis based on this summary, as it contains only standard SEC filing boilerplate language without disclosing any substantive corporate events or developments affecting Strata Critical Medical investors.
Jun 3
8-K · 2.02
!! High
Strata Critical Medical, Inc. -- 8-K 2.02: Earnings Results
Strata Critical Medical reported Q1 2026 financial results, providing investors with updates on operational performance and financial condition for the quarter ending March 31, 2026.
May 6
8-K
Strata Critical Medical, Inc. -- 8-K Filing
Strata Critical Medical reported Q4 2025 earnings from continuing operations, suggesting the company has divested or discontinued certain business segments.
Mar 3
8-K · 1.01
! Medium
Strata Critical Medical, Inc. -- 8-K 1.01: Financing / Debt Agreement
Strata Critical Medical secured a $30 million credit agreement, providing liquidity for operations and potential growth investments while expanding its borrowing capacity.
Feb 5
Institutional (13F) — Top 0
All ↗
No 13F holders found.
Mutual Funds / ETFs (N-PORT) — Top 14
All ↗
| # | Fund | Shares | Value | Period |
|---|---|---|---|---|
| 1 | ARK Autonomous Technology & Robotics ETF | 4,841,053 | $24M | Jan 2026 |
| 2 | ARK Space & Defense Innovation ETF | 2,753,965 | $13M | Jan 2026 |
| 3 | BNY Mellon Small Cap Value Fund | 265,507 | $1M | Mar 2026 |
| 4 | Avantis U.S. Small Cap Equity ETF | 148,794 | $637K | Feb 2026 |
| 5 | Small Cap Value Fund | 107,997 | $451K | Mar 2026 |
| 6 | BNY Mellon Small Cap Multi-Strategy Fund | 63,595 | $272K | Feb 2026 |
| 7 | Small Cap Index Fund | 29,285 | $122K | Mar 2026 |
| 8 | AST Small-Cap Equity Portfolio | 8,840 | $43K | Dec 2025 |
| 9 | Avantis U.S. Small Cap Equity Fund | 6,337 | $27K | Feb 2026 |
| 10 | Avantis U.S. Equity ETF | 4,847 | $21K | Feb 2026 |
| 11 | Innovator U.S. Small Cap Managed Floor ETF | 2,748 | $13K | Jan 2026 |
| 12 | Penn Series Small Cap Index Fund | 1,800 | $8K | Mar 2026 |
| 13 | Russell 2000 Fund | 150 | $627 | Mar 2026 |
| 14 | Russell 2000 1.5x Strategy Fund | 90 | $376 | Mar 2026 |
Valuation
Market Cap
$437.0M
Enterprise Value
$378.4M
P/E (TTM)
8.61x
Forward P/E
—
PEG Ratio
-0.04x
P/B
1.57x
P/S
1.72x
P/FCF
-7.47x
EV/EBITDA
—
Shares Out
82.5M
Financials (TTM)
Revenue
$254.3M
Net Income
$50.8M
EBITDA
-$6.8M
Free Cash Flow
-$58.5M
Op Cash Flow
-$48.9M
EPS Basic
$0.50
EPS Diluted
$-0.16
EPS Forward
$-0.10
Gross Margin
20.5%
Op Margin
-5.9%
Net Margin
20.0%
Balance Sheet
Total Assets
$325.5M
Total Liab.
$46.4M
Total Equity
$279.1M
Cash
$61.2M
LT Debt
$2.7M
Book Value/Sh
$3.38
Debt/Equity
0.01x
Current Ratio
6.38
Quick Ratio
6.38
Returns & Growth
ROE
14.8%
ROA
12.7%
ROIC
15.0%
Rev Growth YoY
-20.7%
EPS Growth YoY
+242.9%
Price Returns
2W
+15.4%
1M
+25.7%
3M
+47.4%
6M
+45.4%
12M
+80.8%
Technicals
52W High
$6.47
52W Low
$3.77
50d MA
$5.48
200d MA
$4.97
RSI (14)
36.20
ATR (14)
$0.28
Beta
2.11
Avg Volume
1.2M
Dividends
Div Rate
$0.00
Div Yield
—
Frequency
—
Ex-Div Date
—
Analyst Price Targets
Consensus
$7.25
High
$7.25
Low
$7.25
Median
$7.25
Data updated apr 27, 2026 2:52am
· Source: financialmodelingprep.com